Skip to main content

Table 1 Characteristics of cases hospitalised with Campylobacter bacteraemia, 2004 to 2013

From: Bacteraemia, antimicrobial susceptibility and treatment among Campylobacter-associated hospitalisations in the Australian Capital Territory: a review

Year (case) Age range/sex Species Bacteraemia—source Antimicrobial susceptibility Antimicrobial treatment Significant medical history and risk factors
2004 80 + M C. jejuni Enteric—secondary Fully sensitive Nil Age, nil other significant
2005 (a) 50–59 F Campylobacter sp. Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd Acute myeloid leukaemia
2005 (b) 60–69 F Campylobacter sp. Enteric—secondary Fully sensitive Nil Nil significant
2005 (c) 40–49 F C. jejuni Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd IV drug use, PUD on omeprazole
2006 (a) 40–49 M C. jejuni Enteric— secondary Fully sensitive PO ciprofloxacin 500 mg bd Untreated Stage III HIV
2008 (a) 20–29 M Campylobacter sp. Enteric—secondary Fully sensitive IV azithromycin 500 mg qd Nil significant
2008 (b) 60–69 M C. coli Primary bacteraemia Ciprofloxacin- Resistant
Erythromycin- Resistant
Nil Lymphocytic lymphoma
2009 30–39 F C. jejuni Enteric—secondary Fully sensitive PO ciprofloxacin 250 mg bd History of renal transplant secondary to IgA nephropathy
2010 (a) 60–69 M Campylobacter sp. Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd Bowel carcinoma, current chemotherapy
2010 (b) 30–39 M C. coli Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd Alcoholic liver disease with portal hypotension and bleeding varices
2010 (c) 70–79 F C. jejuni Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd T2DM
2010 (d) 10–19 F C. jejuni Enteric—secondary Fully sensitive PO azithromycin 500 mg qd (upon discharge) Nil significant.
2010 (e) 70–79 F C. coli Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd T2DM
2010 (f) 40–49 M C. jejuni Enteric—secondary Fully sensitive PO Norfloxacin 400 mg bd Irritable bowel syndrome
2011 (a) 60–69 M C. lari Enteric—secondary Ciprofloxacin— Resistant PO Doxycycline 100 mg bd Alcoholic liver disease with portal hypotension, recent intracerebral bleed
2011 (b) 80 + M C. jejuni Enteric—secondary Fully sensitive Nil prescribed Age, nil other significant
2011 (c) 70–79 M C. coli Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd Asplenic
2012 (a) 40–49 M C. jejuni Enteric—secondary Fully sensitive IV ciprofloxacin 500 mg bd Multiple sclerosis, current chemotherapy pre-stem cell transplantation, IDDM
2012 (b) 30–39 F C. jejuni Enteric—secondary Fully sensitive Nil Pregnant 33/40K, IDDM
2012 (c) 70–79 M C. jejuni Enteric—secondary Ciprofloxacin— Resistant
Nalidixic acid— Resistant
Nil Diabetic neuropathy, chronic renal failure
2012 (d) 60–69 F C. coli Enteric—secondary Ciprofloxacin— Resistant
Nalidixic acid— Resistant
Nil Nil significant
2013 (a) 20–29 M C. jejuni Enteric—secondary Fully sensitive Nil Nil significant
2013 (b) 20–29 M C. jejuni Primary bacteraemia Fully sensitive PO Ciprofloxacin 750 mg bd (upon discharge) B cell leukaemia, AVN (on steroids), SIADH
2013 (c) 50–59 M C. jejuni Enteric—secondary Fully sensitive PO ciprofloxacin 500 mg bd Liver failure with cirrhosis, portal hypotension secondary to Hepatitis C, T2DM, hypothyroidism. Awaiting transplant.
2013 (d) 70–79 M C. jejuni Enteric—secondary Fully sensitive Nil Age, nil other significant
  1. PO, per oral; IV ,  intravenous; PUD, peptic ulcer disease; HIV, human immunodeficiency virus; T2DM, type 2 diabetes mellitus; IDDM, insulin dependent diabetes mellitus; AVN, acute vascular necrosis; SIADH, syndrome of inappropriate antidiuretic hormone